Adam Crystal - Jan 4, 2022 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role
Chief Medical Officer
Signature
/s/ Jolie M. Siegel, Attorney-in-Fact
Stock symbol
CCCC
Transactions as of
Jan 4, 2022
Transactions value $
-$377,618
Form type
4
Date filed
1/5/2022, 03:30 PM
Previous filing
Dec 23, 2021
Next filing
Feb 16, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CCCC Common Stock Options Exercise $97.4K +15K +100% $6.49 30K Jan 4, 2022 Direct F1
transaction CCCC Common Stock Sale -$441K -13.9K -46.49% $31.59* 16.1K Jan 4, 2022 Direct F1, F2
transaction CCCC Common Stock Sale -$34.4K -1.05K -6.57% $32.66* 15K Jan 4, 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CCCC Stock Option (Right to Buy) Options Exercise $0 -15K -11.78% $0.00 112K Jan 4, 2022 Common Stock 15K $6.49 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on January 21, 2021.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.00 to $31.90. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.32 to $33.20. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4 25% of this option vested and became exercisable on February 14, 2020, with the remainder vesting in 16 equal quarterly installments thereafter.